Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains? [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.4% loss over the past four weeks. The sudden rise in the stock price was observed after its competitor firm, Jazz Pharmaceuticals, announced the failure of its mid-stage study evaluating an investigational candidate, suvecaltamide, in adult patients with essential tremor (ET). Praxis' most advanced product candidate, ulixacaltamide (formerly known as PRAX-944), is currently being evaluated in a late-stage study for the ET indication. Topline data from the phase III study is expected in the second half of 2024. The stock price gain signifies that the investors are optimistic about ulixacaltamide's potential to succeed in the late-stage study. This company is expected to post quarterly loss of $2.39 per share in its upcoming report, which represents a year-over-year change of +67.5%. Revenues are expected to be $1.67 million, up 114.1% from the year-ago q
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International CongressGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Participate in Upcoming Investor ConferencesGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $143.00 price target on the stock, up previously from $134.00.MarketBeat
- Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentationsGlobeNewswire
PRAX
Earnings
- 8/13/24 - Beat
PRAX
Sec Filings
- 9/23/24 - Form SC
- 9/3/24 - Form 8-K
- 8/13/24 - Form 10-Q
- PRAX's page on the SEC website